<DOC>
	<DOCNO>NCT00107523</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , idarubicin cytarabine , work different way stop growth cancer cell , either kill cell stop dividing . Pravastatin may help idarubicin cytarabine work well make cancer cell sensitive drug . Giving pravastatin together idarubicin cytarabine may kill cancer cell . PURPOSE : This phase I trial study side effect best dose pravastatin give together idarubicin cytarabine treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Pravastatin , Idarubicin , Cytarabine Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine biological efficacy pravastatin leukemia cell , term measure surrogate endpoint , include cellular cholesterol , messenger RNA encode cholesterol synthesis , cholesterol import regulator , specific protein farnesylation , patient acute myeloid leukemia . - Determine whether increase dos pravastatin , administer idarubicin high-dose cytarabine , produce increase apoptosis leukemia cell patient . - Determine maximum tolerate dose ( MTD ) pravastatin administer idarubicin high-dose cytarabine patient . - Determine whether MTD pravastatin require achieve maximal biological effect cholesterol metabolism leukemia cell patient . OUTLINE : This open-label , multicenter , dose-escalation study pravastatin . Patients receive oral pravastatin daily day 1-8 , idarubicin IV 30 minute day 4-6 , high-dose cytarabine IV continuously day 4-7 . Treatment repeat every 28-42 day 6 course absence disease progression unacceptable toxicity . Patients achieve complete remission ( CR ) may receive additional treatment dos study drug few day . These patient receive oral pravastatin daily day 1-6 idarubicin IV 30 minute high-dose cytarabine IV continuously day 4 5 . Patients experience disease response severe side effect may receive additional treatment lower dose study drug cause side effect . Cohorts 3 patient receive escalate dos pravastatin maximum tolerate dose ( MTD ) * determine predetermined maximum dose reach . NOTE : *Patients achieve CR dose pravastatin subsequently determine MTD receive pravastatin MTD subsequent course . After completion study treatment , patient follow least every 3 month 2 year . PROJECTED ACCRUAL : A total 36 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) meet 1 follow criterion : Newly diagnose disease ( MDACC patient ) In first second relapse AND schedule receive first salvage therapy Primary refractory disease prior induction therapy newly diagnose disease PATIENT CHARACTERISTICS : Age Over 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Not specify Hepatic AST ALT ≤ 2 time normal Alkaline phosphatase ≤ 2 time normal Bilirubin &lt; 2.0 mg/dL No acute chronic hepatic impairment Renal Creatinine &lt; 1.5 time normal ( unless secondary acute myeloid leukemia ) Cardiovascular Ejection fraction ( EF ) ≥ 45 % MUGA 2D echocardiogram Patients EF &lt; 45 % OR cardiac symptom must evaluate cleared cardiology eligible study entry No cardiac contraindication idarubicin Other Not pregnant nursing Fertile patient must use effective contraception HIV negative No uncontrolled life threaten infection No know intolerance study drug Must able safely tolerate 3day delay start pravastatin start chemotherapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No concurrent HMGCoAR inhibitor , include follow : Atorvastatin Fluvastatin Lovastatin Rosuvastatin Simvastatin No concurrent nonHMGCoAR inhibitor low cholesterol No concurrent use follow medication : Bezafibrate Clofibrate Fenofibrate Gemfibrozil Cholestipol Cholestyramine resin Colesevelam Ezetimibe Biphenabid Niacin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>